Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer

xlomafota13 shared this article with you from Inoreader Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer Via In vivo (Athens, Greece) In Vivo. 2021 Mar-Apr;35(2):1211-1215. doi: 10.21873/invivo.12371. ABSTRACT BACKGROUND/AIM: In the CheckMate-141 trial regarding head and neck cancer (HNC), nivolumab conferred a survival benefit to patients. However, the best treatment sequence of chemotherapy and anti-PD-1/PD-L1 therapy in these cancers is unclear. PATIENTS AND METHODS: This was an observational study using data collected prospectively from 97 HNC patients treated with nivolumab at our institutions. Twenty-two HNC patients who received paclitaxel-based chemotherapy before (pre-PTX, n=12) and after (post-PTX, n=10) nivolumab were evaluated. RESULTS: The median follow-up time was 15.9 months (range=6.9-35.9 months). There was a significant difference in the overall response rate (ORR) between pre-PTX (17%) and post-PTX (70%) (p=0.027). Similarly, time to progression (TTP) was significantly longer after nivolumab than before nivolumab (post-PTX, 7.4 months; pre-PTX, 4.9 months, p=0.020). CONCLUSION: Paclitaxel-based chemotherapy had a better ORR and TTP after nivolumab than before nivolumab for HNC. The sequential administration of anti-PD-1 therapy followed by paclitaxel-based chemotherapy could be a better strategy for HNC. PMID:33622923 | DOI:10.21873/invivo.12371 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.